



A REVIEW ON ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR THE DETERMINATION OF N-NITROSODIMETHYLAMINE IN CIPROFLOXACIN TABLETS USING GC-MS/MS

Rakam Gopi Krishna^{1*}, Srigandham Sadhana², Arunabha Mallik³

¹*Department of Pharmaceutical Chemistry, Marri Laxman Reddy Institute of Pharmacy, Dundigal, Hyderabad, Telangana – 500046, India.

²Department of Pharmaceutical Analysis, Marri Laxman Reddy Institute of Pharmacy, Dundigal, Hyderabad, Telangana – 500046, India.

³Department of Pharmacology, Marri Laxman Reddy Institute of Pharmacy, Dundigal, Hyderabad, Telangana – 500046, India.



*Corresponding Author: Rakam Gopi Krishna

Department of Pharmaceutical Chemistry, Marri Laxman Reddy Institute of Pharmacy, Dundigal, Hyderabad, Telangana - 500046, India. Email id: gopirakam@gmail.com, DOI: <https://doi.org/10.5281/zenodo.18803382>

How to cite this Article: Rakam Gopi Krishna^{1*}, Srigandham Sadhana², Arunabha Mallik³. (2026). A Review on Analytical Method Development and Validation for The Determination of N-Nitrosodimethylamine In Ciprofloxacin Tablets Using Gc-Ms/Ms. World Journal of Pharmaceutical and Life Sciences, 12(3), 15–22.

This work is licensed under Creative Commons Attribution 4.0 International license.



Article Received on 04/02/2026

Article Revised on 25/02/2026

Article Published on 01/03/2026

ABSTRACT

N-Nitrosodimethylamine (NDMA) is a highly potent genotoxic impurity that has raised serious safety and regulatory concerns due to its carcinogenic potential. The discovery of NDMA contamination in various pharmaceutical products has necessitated the development of highly sensitive and selective analytical methods for its detection and quantification. Ciprofloxacin, a widely prescribed fluoroquinolone antibiotic, is considered at risk of nitrosamine contamination owing to its synthetic route, raw materials, and formulation processes. This review provides a comprehensive overview of analytical method development and validation strategies for the determination of NDMA in Ciprofloxacin Tablets USP 750 mg, with a specific focus on gas chromatography–tandem mass spectrometry (GC-MS/MS). The article discusses NDMA chemistry, toxicological significance, regulatory expectations, sources of NDMA formation, analytical challenges, sample preparation techniques, chromatographic and mass spectrometric conditions, and validation parameters in accordance with ICH guidelines. Recent advancements, limitations, and future perspectives in NDMA analysis are also highlighted.

KEYWORDS: N-Nitrosodimethylamine, Ciprofloxacin tablets, Nitrosamine impurities, GC-MS/MS, Method development, Method validation.

1. INTRODUCTION

Pharmaceutical impurities have a profound impact on drug safety, quality, and regulatory compliance. Among these, nitrosamine impurities have emerged as a critical concern following their detection in several drug products across multiple therapeutic classes. N-Nitrosodimethylamine (NDMA) is one of the most frequently reported nitrosamines due to its high carcinogenicity and low acceptable intake limits.^[1-4]

Ciprofloxacin is a second-generation fluoroquinolone antibiotic extensively used for the treatment of urinary tract infections, respiratory tract infections, gastrointestinal infections, and systemic bacterial

diseases. Given its widespread use and long-term administration in some patient populations, ensuring the absence of genotoxic impurities such as NDMA in ciprofloxacin tablets is of paramount importance.^[5-7]

The detection of NDMA at trace levels (ng/g or ppb) in complex pharmaceutical matrices presents significant analytical challenges. Gas chromatography coupled with tandem mass spectrometry (GC-MS/MS) has emerged as one of the most reliable techniques for NDMA analysis due to its high sensitivity, selectivity, and robustness. This review critically evaluates the analytical approaches employed for NDMA estimation in ciprofloxacin tablets,

emphasizing method development and validation using GC-MS/MS.^[8-10]

Pharmaceutical quality assurance has undergone increasing scrutiny in recent years due to the detection of nitrosamine impurities such as N-nitrosodimethylamine (NDMA) in approved drug products. NDMA is a low-molecular-weight nitrosamine that has been identified as a potent genotoxic compound capable of inducing tumors in multiple organ systems at low exposure levels. Its occurrence in drugs such as angiotensin receptor blockers (ARBs), ranitidine, and metformin led global regulatory agencies to issue safety alerts, product recalls, and guidance on testing and control strategies.^[11-15]

Ciprofloxacin, a second-generation fluoroquinolone antibiotic, is widely prescribed for combatting both Gram-negative and Gram-positive bacterial infections. Ciprofloxacin tablets are included on the World Health Organization's Model List of Essential Medicines and are administered worldwide. Because of its global utilization and long-term dosing in some therapies, ensuring the absence of genotoxic impurities such as NDMA is critical for patient safety and regulatory compliance.^[16]

Analytical method development for trace-level impurities requires techniques that combine sensitivity, selectivity, and robustness. Gas chromatography coupled with tandem mass spectrometry (GC-MS/MS) has emerged as a gold standard for volatile and semi-volatile nitrosamines, including NDMA, primarily because of its ability to differentiate target analytes from complex pharmaceutical matrices.^[17-20]

This review comprehensively explores the development and validation of GC-MS/MS methods for NDMA determination in ciprofloxacin tablets, highlights regulatory expectations, discusses analytical challenges, and maps recent advances and future perspectives.^[21]

2. N-Nitrosodimethylamine: Chemical and Toxicological Overview

NDMA is a small, volatile, and polar nitrosamine compound with the molecular formula $C_2H_6N_2O$. It is formed through nitrosation reactions involving secondary amines and nitrosating agents such as nitrites under acidic or high-temperature conditions.

Toxicologically, NDMA is classified as a probable human carcinogen (Group 2A) by the International Agency for Research on Cancer (IARC). It has been shown to cause liver toxicity, mutagenicity, and tumor formation in animal studies at extremely low exposure levels. Due to its genotoxic nature, NDMA does not have a safe threshold, necessitating strict regulatory limits.^[22]

Chemical Properties




Fig. 1: N-Nitrosodimethylamine.

N-Nitrosodimethylamine (NDMA) is a semi-volatile organic compound with the chemical formula $C_2H_6N_2O$ and a molecular weight of 74.08 g/mol. It belongs to the N-nitrosamine class, formed by the nitrosation of secondary amines in the presence of nitrosating agents (e.g., nitrites) under acidic or elevated temperature conditions. NDMA is soluble in water, organic solvents such as methanol and dichloromethane, and exhibits moderate volatility—making it amenable to headspace gas chromatography techniques.^[23-24]

Toxicological Significance

NDMA is classified by the International Agency for Research on Cancer (IARC) as a Group 2A carcinogen (probable human carcinogen). Extensive animal studies have demonstrated hepatic carcinogenicity at microgram-level exposures, and NDMA has been shown to induce DNA alkylation, contributing to mutagenesis. Its genotoxicity is linked to metabolic activation in the liver via cytochrome P450 enzymes. Acute and chronic exposure may also lead to liver toxicity, reproductive toxicity, and systemic adverse effects.^[25-27]

Because NDMA exhibits no clear threshold below which genotoxic effects are absent, regulatory bodies have set extremely low acceptable intake (AI) levels for NDMA in pharmaceuticals, typically in the low nanogram per day range.

3. Regulatory Landscape for NDMA in Pharmaceuticals

Global regulatory authorities have issued stringent guidelines to control nitrosamine impurities in pharmaceuticals:

- * US FDA: Mandates risk assessment, confirmatory testing, and reporting of NDMA levels.
- * EMA: Requires manufacturers to identify and mitigate nitrosamine risks.
- * ICH M7: Provides guidance on the assessment and control of DNA-reactive impurities.

The acceptable intake (AI) limit for NDMA is generally set at 96 ng/day, though lower limits may apply depending on treatment duration and patient exposure. Analytical methods must therefore achieve detection limits well below this threshold.^[28]

Global regulatory agencies have issued guidance and mandatory requirements for the control and testing of NDMA and other nitrosamines in drugs:

FDA (USA): Issued guidance on risk assessment and control strategies for nitrosamine impurities. It established acceptable intake limits and recommended validated analytical testing for NDMA in active pharmaceutical ingredients (APIs) and finished products.

EMA (European Union): Released a detailed guideline requiring manufacturers to evaluate potential nitrosamine formation pathways and implement control strategies. It emphasizes risk assessment and requires appropriate analytical methods with defined performance characteristics.

ICH Q3A/B: Covers impurity evaluation and reporting limits in pharmaceuticals but has been supplemented by specific nitrosamine guidance due to the unique toxicological profiles of these compounds.^[29-31]

USP General Chapter <1469> (United States Pharmacopeia): Provides procedures for nitrosamine detection, including method recommendations and performance criteria.

Regulatory expectations include: ✓

- Comprehensive risk assessment throughout synthesis and formulation.
- Use of validated methods capable of detecting NDMA well below accepted intake limits (often ≤ 100 ng/day equivalent). ✓
- Demonstration of method specificity, sensitivity, accuracy, precision, robustness, and stability. ✓

4. Sources of NDMA in Ciprofloxacin Tablets ✓

NDMA contamination in ciprofloxacin tablets may arise from several sources:

- * Use of dimethylamine or secondary amines in synthesis ✓
- * Presence of nitrite impurities in raw materials ✓
- * Solvent degradation during manufacturing
- * Cross-contamination during production
- * Packaging and storage conditions

Understanding these sources is essential for both analytical method development and risk mitigation.^[32]

NDMA in ciprofloxacin tablets may arise from multiple pathways:

- ✚ **Synthesis-Related Formation:** Use of dimethylamine precursors or nitrosating agents in the synthesis of ciprofloxacin or intermediates can lead to residual NDMA formation.
- ✚ **Excipient Contamination:** Excipients containing secondary amines or nitrosating impurities (e.g., sodium nitrite) may react under formulation conditions.
- ✚ **Solvent Impurities:** Solvents used during synthesis or formulation may contain nitrosating agents that facilitate NDMA formation.^[33]

✚ **Process Conditions:** Elevated temperatures and acidic environments during manufacturing can catalyze nitrosation reactions.

✚ **Cross-Contamination:** Shared equipment without effective cleaning protocols may transfer nitrosamines from one production batch to another.

Understanding these sources is crucial for analytical strategy and process control.

5. Analytical Challenges in NDMA Determination

The estimation of NDMA in ciprofloxacin tablets is analytically demanding due to:

- * Extremely low regulatory limits
- * Volatile and thermally stable nature of NDMA
- * Matrix interference from API and excipients
- * Risk of in-situ NDMA formation during analysis

These challenges necessitate the use of highly selective and sensitive analytical techniques.

Quantifying NDMA in pharmaceutical matrices such as ciprofloxacin tablets presents several key challenges^[34]:

Trace-Level Detection: Regulatory limits for NDMA are extremely low (nanogram per day intake), often requiring detection limits in the parts-per-billion (ppb) or lower range.

Matrix Interference: Excipients and APIs may co-elute or suppress ionization, complicating quantification.

Artifact Formation: Sample preparation conditions may inadvertently generate NDMA from precursors, leading to false positives.

Volatility and Stability: NDMA's volatile nature necessitates careful handling and suitable analytical techniques, such as headspace sampling or optimized GC conditions.

Instrument Requirements: High sensitivity and selectivity instruments (GC-MS/MS) are required, which demand skilled operators and rigorous quality control.^[35]

6. Overview of Analytical Techniques for NDMA Analysis

Several analytical techniques have been reported for NDMA determination:

6.1 LC-MS/MS

While widely used, LC-MS/MS may suffer from matrix suppression and limited sensitivity for volatile nitrosamines.^[36]

6.2 GC-MS

GC-MS offers better volatility compatibility but may lack sufficient selectivity at ultra-trace levels.

6.3 GC-MS/MS

GC-MS/MS operating in multiple reactions monitoring (MRM) mode provides superior sensitivity, selectivity, and reproducibility, making it the preferred technique for NDMA analysis in pharmaceuticals.^[37-40]




Fig. 2: Schematic Diagram of GC-MS/MS

Table 1: Multiple Analytical Approaches Have Been Applied To NDMA Determination.

Technique	Principle	Pros	Cons
GC-MS	Separates volatile analytes by gas chromatography, detects by mass spectrometry	Good separation, established technology	Limited sensitivity for ultra-trace levels
GC-MS/MS	Tandem mass spectrometry with multiple reaction monitoring (MRM)	Superior selectivity & sensitivity	Costly, requires expertise
LC-MS/MS	Liquid chromatography coupled to tandem MS	Applicable to non-volatile analytes	Often lower sensitivity for volatile nitrosamines
Headspace GC-MS(/MS)	Volatile compounds measured from headspace	Minimizes matrix	Optimization required to avoid artifact formation
SPE + GC-MS/MS	Solid-phase cleanup before GC	Reduces matrix interference	Additional prep time

Discussion: GC-MS/MS stands out as the preferred method for volatile nitrosamines like NDMA due to its ability to isolate target compounds from complex matrices using MRM, greatly improving signal-to-noise ratios compared to single-quadrupole GC-MS. LC-

MS/MS can be used for less volatile nitrosamines or when GC analyzability is an issue, but its applicability for NDMA in ciprofloxacin is limited due to NDMA's volatility and low molecular weight.

7. REVIEW OF LITERATURE OF NDMA^[41-47]

Table 2: Reported GC-MS/MS Methods for NDMA in Pharmaceuticals.

Reference	Drug Matrix	Sample Prep	Detection	LOD/LOQ	Key Findings
Lim et al., 2020	Sartans	Headspace	GC-MS/MS	<0.5 ng/mL	Effective for NDMA/NDEA
Zou et al., 2023	Metformin HCl	SPE + GC-MS/MS	GC-MS/MS	<1 ng/mL	High recovery using SPE
Derringer et al., 2020	Ranitidine	HS-GC-MS/MS	GC-MS/MS	~0.2 ng/mL	Differentiated NDMA from matrix
Zhao et al., 2021	Sartan API	Liquid extraction + GC-MS/MS	GC-MS/MS	~0.3 ng/mL	Validated protocol
Mohanareddy et al., 2025	Zidovudine	SPE + GC-MS/MS	GC-MS/MS	~0.8 ng/mL	Good precision & accuracy

Discussion: Across multiple drug matrices, GC-MS/MS has reliably achieved ultra-trace detection of NDMA (often <1 ng/mL), demonstrating its general applicability. Sample preparation varied from direct

headspace techniques to SPE cleanup, indicating flexibility based on matrix complexity.

8. GC-MS/MS Method Development for NDMA in Ciprofloxacin Tablets

8.1 Sample Preparation

Sample preparation is critical to minimize matrix interference and avoid artificial NDMA formation. >

Common approaches include: >

* Solvent extraction using methanol or dichloromethane

* Solid-phase extraction (SPE) for cleanup

* Filtration and concentration steps

The choice of extraction solvent and conditions significantly affects recovery and reproducibility.^[48]

8.2 Chromatographic Conditions

Optimized GC conditions typically include:

* Capillary columns such as DB-624 or equivalent

* Helium as carrier gas

* Temperature-programmed oven conditions

Proper chromatographic separation ensures minimal interference and accurate quantification.^[49]

8.3 Mass Spectrometric Detection

Electron impact ionization is commonly used for NDMA analysis. In GC-MS/MS, specific precursor-to-product ion transitions are monitored, significantly enhancing selectivity and lowering detection limits.

9. METHOD VALIDATION ACCORDING TO ICH GUIDELINES

Analytical methods must be validated as per ICH Q2(R1) guidelines.^[50-54]

9.1 Specificity

Ability to unequivocally assess NDMA in the presence of ciprofloxacin and excipients.

Ability of the method to unequivocally assess NDMA in the presence of ciprofloxacin and excipients.^[55]

Verified through

- ✓ Blank matrix analysis
- ✓ Spiked matrix preparations
- ✓ Confirmation via multiple MRM transitions

9.2 Linearity

Typically demonstrated over a low ng/mL concentration range.

Demonstrated by analyzing calibration standards over a defined range, often down to low ppb concentrations.^[56-57]

Linearity typically requires

- > Correlation coefficient (r^2) ≥ 0.99
- > Consistent response across calibration levels

9.3 Accuracy

Evaluated through recovery studies at multiple spiking levels.

Assessed by recovery studies at multiple spiking levels (e.g., 1 ng/g, 5 ng/g, 10 ng/g). Acceptable recovery: 80–120% (varies by guideline and matrix).^[58-59]

9.4 Precision

Includes repeatability and intermediate precision.

Evaluated as

Repeatability (intra-day): Same day analyses

Intermediate precision (inter-day): Across days, analysts

Precision usually expressed as %RSD $\leq 15\%$.^[60]

9.5 LOD and LOQ

Critical parameters ensuring compliance with regulatory limits.

Limits defined using signal-to-noise ratios (LOD ~3:1, LOQ ~10:1) or statistical approaches. Methods typically achieve LOQs <1 ng/g.^[61-62]

9.6 Robustness

Assesses method reliability under small variations in conditions.

Assessed by deliberate small changes in method conditions (e.g., temperature, flow rate) to confirm method stability.

Validated GC-MS/MS methods consistently demonstrate LOQs well below regulatory thresholds.⁶³

10. Applications in Quality Control and Regulatory Compliance

GC-MS/MS methods are increasingly used for:

* Routine quality control testing of finished ciprofloxacin batches

* Stability studies to assess NDMA formation over time

* Regulatory submissions by pharmaceutical manufacturers

* Risk assessment and mitigation strategies required by regulators

Their robustness and sensitivity make them suitable for long-term monitoring of NDMA in ciprofloxacin tablets.

These tests ensure that NDMA does not exceed acceptable intake limits and that the product meets safety criteria before market release.^[64]

11. Recent Advances and Emerging Trends

Recent developments include

❖ Automated sample preparation: SPE automation and robotic headspace systems reduce variability and increase throughput.

❖ Microextraction techniques: Headspace solid-phase microextraction (HS-SPME) improves detection without solvents.

❖ High-resolution MS (HRMS): Provides exact mass confirmation, beneficial in complex matrices.

❖ Green analytical techniques: Minimize solvent use and waste.

❖ AI-Assisted data processing: Improves peak recognition and quantification reliability.

These advancements aim to improve throughput, accuracy, and sustainability.^[65]

12. Limitations and Challenges

Despite its advantages, GC-MS/MS has limitations:

- * High instrument costs remain high, limiting accessibility.
 - * Requirement for skilled personnel
 - * Potential for contamination if not properly controlled
 - * Expertise requirements for GC-MS/MS operation and data interpretation.
 - * Matrix complexity can still pose interference challenges.
 - * Artifact generation risks if sample prep conditions are not carefully controlled.
- Continuous method optimization is necessary to overcome these challenges.

13. Future Perspectives

Future research should focus on:

- * Preventive strategies for NDMA formation
- * Standardized analytical protocols mandated across pharmacopeias.
- * Integration of analytical and manufacturing controls
- * Real-time monitoring technologies during manufacturing.
- * Expanded green analytical chemistry principles to improve sustainability.

Such approaches will enhance pharmaceutical safety and regulatory compliance.

14. CONCLUSION

The determination of NDMA in Ciprofloxacin Tablets USP 750 mg is a critical requirement driven by patient safety and regulatory expectations. GC-MS/MS has emerged as a powerful analytical tool due to its exceptional sensitivity and selectivity for trace-level NDMA analysis. Comprehensive method development and rigorous validation are essential to ensure accurate, reliable, and reproducible results. This review highlights the importance of GC-MS/MS-based analytical methodologies in safeguarding pharmaceutical quality and underscores the need for continuous advancement in impurity analysis.

NDMA contamination in pharmaceuticals poses significant risks to public health and regulatory compliance. GC-MS/MS has proven to be a powerful analytical technique for the trace determination of NDMA in ciprofloxacin tablets due to its high sensitivity, selectivity, and adaptability to volatile analytes. Careful method development, rigorous validation per ICH guidelines, and appropriate application in quality control are paramount to ensure patient safety. Although challenges remain, continued advancements in analytical science will facilitate more efficient, accurate, and sustainable testing strategies.

ACKNOWLEDGMENTS

The authors acknowledge the contributions of regulatory agencies and researchers whose work has advanced nitrosamine analysis in pharmaceuticals.

The management of Marri Laxman Reddy Institute of Pharmacy, Dundigal, Hyderabad, Telangana, India, is appreciated by the authors for Providing the resources needed to complete the review.

Conflicts of Interest

The authors declare no conflicts of interest.

15. REFERENCES

1. Lim HH, Oh YS, Shin HS. Determination of N-nitrosodimethylamine and N-nitrosodiethylamine in Sartans and metformin raw materials and finished products by headspace GC-MS/MS. *Bull Korean Chem Soc*, 2020; 41(6): 897-905.
2. Zou JJ, et al. Method validation and monitoring of N-nitrosodimethylamine in metformin hydrochloride products in China by GC-MS/MS. *Curr Pharm Anal*, 2023; 19: 759-766.
3. Lim HH, Oh YS, Shin HS. Determination of N-nitrosodimethylamine and N-nitrosomethylethylamine in drug substances and products of Sartans, metformin, and ranitidine by GC-MS/MS. *J Pharm Biomed Anal.*, 2020; 189: 113460.
4. Shomali F, et al. Analysis and risk assessment of nitrosamines in Sartans using GC-MS and Monte Carlo simulation. *Sci Rep.*, 2025; (in press).
5. Mohanareddy C, et al. A novel validated GC-MS/MS method for estimation of NDMA and NDEA in Zidovudine. *J Chromatogr Sci.*, 2025; 62(5): 399-405.
6. Zhao Y, et al. Development of a sensitive and stable GC-MS/MS method for simultaneous determination of N-nitrosamines in Sartans substances. *J Anal Sci Technol*, 2021; 12: 3.
7. Analysed GC-MS/MS method for simultaneous estimation of four Nitrosoamine genotoxic impurities in valsartan. *Turk J Pharm Sci.*, 2021; 18(3): 17702.
8. Headspace GC-MS method to quantify nitrosamine impurities and precursors in drug products: method validation and product testing. *J Pharm Biomed Anal.* 2024; (NDMA detection in Sartan/metformin products).
9. Valsartan NDMA impurity and analytical methods for N-nitrosamines: a review. *J Pharm Anal.* 2024; (focus on GC-MS/MS).
10. Manchuri KM, et al. An update on latest regulatory guidelines and analytical methodologies concerning N-nitrosamine impurities. *Med Gas Res.*, 2025.
11. Manchuri KM. Analytical methodologies to detect N-nitrosamine impurities: a critical review. *Chem Res Toxicol*, 2024; (review of GC-MS, LC-MS methods).
12. Manchuri KM. Analytical methods for N-nitrosamines: availability and regulatory relevance. *PMC*, 2024.
13. FDA Guidance for Industry. Control of Nitrosamine Impurities in Human Drugs. Silver Spring, MD: FDA, 2023. ([U.S. Food and Drug Administration])

14. Vikram HPR, et al. Nitrosamines crisis in pharmaceuticals – insights on toxicity, control and analysis. *Chem Biol Interact*, 2024; (review).
15. Derringer G, et al. Development and validation of headspace GC-MS/MS methods for NDMA in APIs and formulations. *J Pharm Biomed Anal*, 2020; 191: 113582.
16. Alshehri YM, Alghamdi TS, Aldawsari FS. HS-SPME-GC-MS as alternative method for NDMA analysis. *J Pharm Biomed Anal*, 2020; 191: 113582. (PMC)[2]
17. Giménez-Campillo C, et al. New methodology for determination of N-nitrosamines in ranitidine using Microextraction and GC-MS. *Talanta*, 2021; 223: 121659.
18. Wichitnithad W, et al. Headspace GC-MS determination of nitrosamines in losartan APIs. *ACS Omega*, 2021; 6: 11048-11058.
19. Planinšek Parfant T, Skube T, Roškar R. Simultaneous quantification of 13 nitrosamines in pharmaceuticals by LC-HRMS. *Eur J Pharm Sci.*, 2024; 192: 106633.
20. Mavis ME, Gursu GG, Cagatay NU. LC-APCI-MS/MS for simultaneous determination of eleven nitrosamines in Sartans. *J Chromatogr B.*, 2023; 1216: 123593.
21. FDA LC-HRMS methods for determination of six nitrosamine impurities in ARB drugs. US FDA Technical Report, 2019.
22. González R, Torrado G, Arribas JM, Peña MA. HPLC-MS/MS determination of NDMA in Olmesartan. *Microchem J.*, 2022; 179: 107402.
23. Ishizaki A, Ozawa K, Kataoka H. Simultaneous analysis of NDMA in metformin tablets using LC-MS with solid-phase Microextraction. *J Chromatogr A.*, 2023; 1710: 464416.
24. National Institute of Health. Method for four nitrosamine impurities in Sartans using HPLC-MS/MS. NIH Report, 2022.
25. Řemínek R, Foret F, Chung DS. Capillary electrophoresis-nano-ESI-MS for NDMA in pharmaceuticals. *Electrophoresis*, 2021; 42: 334-341.
26. Boczar D, et al. Semi-quantitative determination of nitrosamines in Enalapril maleate by HPLC with fluorimetric detection. *Appl Sci.*, 2021; 11: 7590.
27. Kirakosyan VG, et al. Quantitative determination of NDMA in various drugs by HPLC. *Proc YSU B Chem Biol Sci.*, 2021; 55: 296-299.
28. ICH Q2 (R1). *Guidance on validation of analytical methods (ICH Q2 (R1))*. Geneva: ICH; 2005. ([U.S. Food and Drug Administration])
29. EMA Guideline on nitrosamines in human medicinal products. EMA, 2020.
30. US Pharmacopeia General Chapter <1469> Nitrosamine Impurities – Procedures for Detection and Quantification. USP, 2023.
31. Rakam Gopi Krishna, Satya Lahari Boddu, Samhitha Damera, Akash Kumar Kadapa, Krishna Mohan Reddy Dharmareddy and Charithaa Katha. *Advances in Anti-Tubercular Agents: A Comprehensive Review*. *Biomedical & Pharmacology Journal*, 2025; 18(1): 547-558.
32. Rakam Gopi Krishna, Kadagoni Pravalika, Ramesh Konda, V A N V Harita, G. Haritha. Analytical Method Development and Validation of Remdesivir and Griseofulvin in API and its Dosage Form by RP-HPLC. *International Journal of Drug Delivery Technology*, 2025; 15(1): 139-45. Doi: 10.25258/ijddt.15.1.19.
33. Rakam Gopi Krishna, M. Srinivasa Murthy, V. Kavya. Method development and validation of RP-HPLC method for the determination of Sumatriptan in Bulk and Pharmaceutical Dosage form. *Research Journal of Pharmacy and Technology*, 2021; 14(11): 5856-2.
34. Gopi Krishna Rakam, Raja Sundararajan. In vitro antioxidant activity of Bougainvillea glabra and Mucuna pruriens. *International Journal of Research in Pharmaceutical Sciences*, 2020; 11(1): 806-812.
35. Rakam Gopi Krishna and Raja Sundararajan. Screening of antioxidant activity of Mucuna pruriens by in vivo model. *International Journal of Research in Pharmaceutical Sciences*, 2018; 10(1): 523-530.
36. Kuchi Manjeera and Raja Sundararajan. Toxicity Studies of Abutilon crispum and Indigofera prostrata Whole Plants on Wistar Rats. *Tropical journal of Natural Product Research*, 2024; 8(11): 9073-9078.
37. Kuchi Manjeera and Raja Sundararajan. Standardization and Phytochemical screening of Abutilon crispum. *Research Journal of Pharmacy and Technology*, 2024; 17(4): 1621-1630.
38. Kuchi Manjeera and Raja Sundararajan. Evaluation of Antidiabetic Activity of Indigofera prostrata on Normal and Streptozotocin Induced Diabetic Albino Wistar Rats. *Journal of Natural Remedies*, 2024; 24(10): 2217-2230.
39. Kuchi Manjeera and Raja Sundararajan. Evaluation of Antidiabetic Activity of Abutilon crispum on Normal and Streptozotocin Induced Diabetic Albino Wistar Rats. *Journal of Pharmacology and Pharmacotherapeutics (SAGE Journals)*, 2024; 16(1): 64-76.
40. Kuchi Manjeera and Raja Sundararajan. In vitro antidiabetic activity of Indigofera prostrata. *Advances in Pharmacology and Pharmacy (HR Publications)*, 2025; 13(3): 333-341.
41. Rakam Gopi Krishna, Afshan Nausheen, Bethi Ganga Shivani, Ruthika Kingari, Konale Pallavi. Advances in Novel Drugs, Plants and Phytoconstituents proved for Antioxidant Activity - A Comprehensive Review. *Research Journal of Pharmacy and Technology*. Accepted for Publication in, 2026; 19(2).
42. Kuchi Manjeera, Rakam Gopi Krishna, V.A.N.V. Harita, Suwendu Saha, Ch. Sandeep Reddy. Preliminary Phytochemical Screening and Antibacterial Activity of Anthocephalus Cadamba Whole Plant. *Vignán's Journal of Biotechnology and Pharmacy*, 2025; 1(1): 8-14.

43. Rakam Gopi Krishna and Kuchi Manjeera. Medicinal Herbs and Phytoconstituents Proved for Anticancer Activity-A Comprehensive Review. *Current Trends in Pharmacology and Clinical Trials*, 2025; 8(1): 1-16.
44. Kadagoni P, Rakam GK, Rani J, Reddy R, Gari SRJ and Kalisetty AS. A Review on Decoding Diabetic Foot Ulcers. *Current Scientific Research in Biomedical Sciences*, 2024; 6(1): 1-7.
45. Rakam Gopi Krishna, Kadagoni Pravalika, Nikhil Reddy, Bhavani Sandhya, Shrenitha, Aradhana. A Review on Collection of Herbs Used for the Treatment of Psoriasis. *International Journal of Pharmaceutical Research and Applications*, 2024; 9(6): 158-166.
46. Rakam Gopi Krishna, N. Vinuthna, T. Sushmitha, V. Mounika, T. Manikanta. Extraction, Preliminary Phytochemical Screening & Antibacterial Activity of Terminalia Chebula Fruit. *International Journal of Allied Medical Sciences and Clinical Research*, 2024; 12(3): 285-292.
47. Krishna RG, Nausheen A, Shivani BG, Kingari R, Pallavi K, Saha S. Extraction, Investigation of Phytochemical Composition, and In Vitro Antioxidant Activity of Indigofera Cordifolia. *J. Pharma. QAQC*, August 02, 2025; 7(2): 27-36.
48. V.A.N.V. Haritha, Rakam Gopi Krishna, Alapati Geethika, Boddu Harika, Goppa Saraswathi, Gayakwad Rajeshwar. Phytochemical Screening & Comparative study of different extracts on Antifungal Activity of Neolamarckia Cadamba leaf. *International Journal of Research in Pharmacology & Pharmacotherapeutics*, 2024; 13(3): 254-264.
49. Dr. Suvendu Saha, L. Gnana Prasanna, S. Prathyusha, Shainazz, S. Sai Kiran, Abhishek Samadhar, Dr. Rakam Gopi Krishna. Anticonvulsant Activity of Moringa oleifera in Swiss Albino Mice. *Journal for Innovative Development in Pharmaceutical and Technical Science*, 2024; 7(7): 1-5.
50. G. K. Rakam, Arunabha Mallik and Ch. Sucharitha. Method Development and Validation of RP-HPLC Method for Estimation of Ondansetron and Pantoprazole in their Tablet Dosage Form. (*Indian Journal of Pharmaceutical Sciences*) Scopus Indexed Journal, 2022; 84(2): 483-492.
51. Rakam Gopi Krishna, V. Sindusha, A. V. Thanmayi, J. Vignesh, S. Krishna Reddy, K. Himabindu. Screening and evaluation of antimicrobial activity of ethanolic extract of plant Muntingia Calabura. *Journal of Global Trends in Pharmaceutical Sciences*, 2022; 13(3): 53-58.
52. Rakam Gopi Krishna and Raja Sundararajan. Toxicity studies of Bougainvillea glabra and Mucuna pruriens. *International Journal of Pharmaceutical Sciences and Research*, 2020; 11(10): 4910-4917.
53. Rakam Gopi Krishna and Raja Sundararajan. Myocardial Protective Impact of Mucuna pruriens on Isoproterenol Prompted Myocardial Necrosis. *Scholars Research Library, Der Pharmacia Lettre*, 2018; 10(3): 37-56.
54. Rakam Gopi Krishna and Raja Sundararajan. Cardioprotective and antioxidant effects of Bougainvillea glabra against isoproterenol induced myocardial necrosis in albino rats. *International Journal of Phytomedicine*, 2018; 10(1): 45-57.
55. Rakam Gopi Krishna, Raja Sundararajan. In vivo Antioxidant Activity of Bougainvillea glabra. *IOSR Journal of Pharmacy*, 2018; 8(6): 11-18.
56. Rakam Gopi Krishna and Raja S. Molecular Docking Study of Isolated Phytoconstituents from Bougainvillea glabra And Mucuna pruriens. *European Journal of Biomedical and Pharmaceutical sciences*, 2018; 5(11): 386-394.
57. Rakam Gopi Krishna & Raja Sundararajan. A complete evaluation on Bougainvillea glabra: Ethnomedical information, Active constituents & Pharmacological actions. *American Journal of Pharm Tech Research*, 2017; 7(1).
58. Rakam Gopi Krishna, Raja S. Standardization and Phytochemical Screening of Bougainvillea glabra. *International Journal of Current Pharmaceutical Research*, 2017; 9(5).
59. Rakam Gopi Krishna and Raja Sundararajan. Standardization and Phytochemical Screening of Mucuna Pruriens. *European Journal of Biomedical and Pharmaceutical sciences*, 2017; 4(11).
60. Rakam Gopi Krishna, Kuchi Manjeera, Repudi Lalitha, Nadumula Sunitha. Preliminary phytochemical screening and in vitro antibacterial activity of Bridelia retusa plant extract. *World Journal of Pharmaceutical Research*, 2013; 2(6): 3337-3347.
61. Gopi KR, Manjeera K, Lalitha R. A validated spectrophotometric method for the estimation of ezetimibe in bulk and tablet dosage form. *Indo American Journal of Pharmaceutical Research*, 2014; 4(4): 1799-1803. DOI: 10.1044/1980-iajpr.472.
62. Raja Sundararajan, Gopi Krishna Rakam, Ravindranadh Konduru. Evaluation of antioxidant and cardio protective activities of Bridelia retusa on isoproterenol induced myocardial necrosis in albino rats. *World Journal of Pharmaceutical Research*, 2014; 3(3): 4549-4572.
63. Kumaraswamy. Gandla, R. Lalitha, Konam Kishore and Rakam Gopi Krishna. A Validated RP-HPLC Method for Simultaneous Estimation of Aspirin and Rosuvastatin in Tablet Dosage Form. *International Journal of Pharma and Chemical Research*, 2015; 1(3): 128-133.
64. N. Sunitha, R. Gopi Krishna, R. Lalitha and V. Rajkumar. Synthesis and Biological Evaluation of New Thiazolidinone Derivatives. *International Journal of Medicinal Chemistry & Analysis*, 2016; 6(1): 19-26.
65. Akunuri Premalatha, V. Raj Kumar, Rakam Gopi Krishna and Kuchi Manjeera. Formulation and evaluation of Tramadol Hcl sustained Release Matrix Tablets. *World Journal of Pharmaceutical Research*, 2015; 4(5).